nodes	percent_of_prediction	percent_of_DWPC	metapath
Rabeprazole—ABCG2—Fluorouracil—urinary bladder cancer	0.0744	0.135	CbGbCtD
Rabeprazole—ABCG2—Carboplatin—urinary bladder cancer	0.0739	0.134	CbGbCtD
Rabeprazole—ABCG2—Cisplatin—urinary bladder cancer	0.0632	0.115	CbGbCtD
Rabeprazole—ABCG2—Etoposide—urinary bladder cancer	0.0621	0.113	CbGbCtD
Rabeprazole—CYP3A4—Thiotepa—urinary bladder cancer	0.0495	0.0898	CbGbCtD
Rabeprazole—ABCG2—Doxorubicin—urinary bladder cancer	0.0423	0.0769	CbGbCtD
Rabeprazole—ABCG2—Methotrexate—urinary bladder cancer	0.041	0.0745	CbGbCtD
Rabeprazole—CYP1A2—Fluorouracil—urinary bladder cancer	0.0307	0.0557	CbGbCtD
Rabeprazole—CYP2C9—Fluorouracil—urinary bladder cancer	0.0276	0.0502	CbGbCtD
Rabeprazole—CYP1A2—Etoposide—urinary bladder cancer	0.0256	0.0465	CbGbCtD
Rabeprazole—CYP2C9—Cisplatin—urinary bladder cancer	0.0235	0.0426	CbGbCtD
Rabeprazole—CYP2D6—Doxorubicin—urinary bladder cancer	0.0144	0.0261	CbGbCtD
Rabeprazole—CYP3A4—Etoposide—urinary bladder cancer	0.0134	0.0244	CbGbCtD
Rabeprazole—CYP3A4—Doxorubicin—urinary bladder cancer	0.00915	0.0166	CbGbCtD
Rabeprazole—CYP2C19—urine—urinary bladder cancer	0.00503	0.113	CbGeAlD
Rabeprazole—CYP1A2—urine—urinary bladder cancer	0.00411	0.0924	CbGeAlD
Rabeprazole—CYP2C9—urine—urinary bladder cancer	0.0039	0.0877	CbGeAlD
Rabeprazole—ATP4A—epithelium—urinary bladder cancer	0.0038	0.0854	CbGeAlD
Rabeprazole—ATP4A—renal system—urinary bladder cancer	0.00352	0.0793	CbGeAlD
Rabeprazole—CYP3A4—urine—urinary bladder cancer	0.00297	0.0669	CbGeAlD
Rabeprazole—CYP2D6—urine—urinary bladder cancer	0.00293	0.0658	CbGeAlD
Rabeprazole—ATP4A—female reproductive system—urinary bladder cancer	0.00282	0.0635	CbGeAlD
Rabeprazole—ABCG2—prostate gland—urinary bladder cancer	0.00153	0.0345	CbGeAlD
Rabeprazole—ABCG2—seminal vesicle—urinary bladder cancer	0.0013	0.0292	CbGeAlD
Rabeprazole—CYP1A1—epithelium—urinary bladder cancer	0.00107	0.024	CbGeAlD
Rabeprazole—ABCG2—urethra—urinary bladder cancer	0.00103	0.0231	CbGeAlD
Rabeprazole—CYP1A2—renal system—urinary bladder cancer	0.001	0.0226	CbGeAlD
Rabeprazole—CYP1A1—renal system—urinary bladder cancer	0.000991	0.0223	CbGeAlD
Rabeprazole—CYP1A1—urethra—urinary bladder cancer	0.000974	0.0219	CbGeAlD
Rabeprazole—CYP2C19—vagina—urinary bladder cancer	0.000891	0.0201	CbGeAlD
Rabeprazole—CYP1A1—female reproductive system—urinary bladder cancer	0.000794	0.0179	CbGeAlD
Rabeprazole—CYP2C9—female reproductive system—urinary bladder cancer	0.000764	0.0172	CbGeAlD
Rabeprazole—ABCG2—vagina—urinary bladder cancer	0.000756	0.017	CbGeAlD
Rabeprazole—CYP3A4—renal system—urinary bladder cancer	0.000727	0.0164	CbGeAlD
Rabeprazole—CYP1A1—vagina—urinary bladder cancer	0.000718	0.0162	CbGeAlD
Rabeprazole—CYP2D6—renal system—urinary bladder cancer	0.000716	0.0161	CbGeAlD
Rabeprazole—CYP3A4—female reproductive system—urinary bladder cancer	0.000582	0.0131	CbGeAlD
Rabeprazole—CYP2D6—female reproductive system—urinary bladder cancer	0.000573	0.0129	CbGeAlD
Rabeprazole—ABCG2—lymph node—urinary bladder cancer	0.000489	0.011	CbGeAlD
Rabeprazole—CYP1A1—lymph node—urinary bladder cancer	0.000464	0.0104	CbGeAlD
Rabeprazole—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000142	0.00047	CcSEcCtD
Rabeprazole—Pneumonia—Doxorubicin—urinary bladder cancer	0.000141	0.000468	CcSEcCtD
Rabeprazole—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000141	0.000468	CcSEcCtD
Rabeprazole—Pruritus—Fluorouracil—urinary bladder cancer	0.000141	0.000467	CcSEcCtD
Rabeprazole—Visual impairment—Methotrexate—urinary bladder cancer	0.00014	0.000465	CcSEcCtD
Rabeprazole—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000139	0.000462	CcSEcCtD
Rabeprazole—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000139	0.000461	CcSEcCtD
Rabeprazole—Bradycardia—Epirubicin—urinary bladder cancer	0.000139	0.00046	CcSEcCtD
Rabeprazole—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000138	0.000459	CcSEcCtD
Rabeprazole—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000138	0.000457	CcSEcCtD
Rabeprazole—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000138	0.000457	CcSEcCtD
Rabeprazole—Urticaria—Etoposide—urinary bladder cancer	0.000137	0.000455	CcSEcCtD
Rabeprazole—Stomatitis—Doxorubicin—urinary bladder cancer	0.000137	0.000454	CcSEcCtD
Rabeprazole—Jaundice—Doxorubicin—urinary bladder cancer	0.000137	0.000454	CcSEcCtD
Rabeprazole—Rhinitis—Epirubicin—urinary bladder cancer	0.000137	0.000453	CcSEcCtD
Rabeprazole—Abdominal pain—Etoposide—urinary bladder cancer	0.000136	0.000453	CcSEcCtD
Rabeprazole—Body temperature increased—Etoposide—urinary bladder cancer	0.000136	0.000453	CcSEcCtD
Rabeprazole—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000136	0.000453	CcSEcCtD
Rabeprazole—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000136	0.000453	CcSEcCtD
Rabeprazole—Hepatitis—Epirubicin—urinary bladder cancer	0.000136	0.000452	CcSEcCtD
Rabeprazole—Eye disorder—Methotrexate—urinary bladder cancer	0.000136	0.000451	CcSEcCtD
Rabeprazole—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000136	0.000451	CcSEcCtD
Rabeprazole—Tinnitus—Methotrexate—urinary bladder cancer	0.000136	0.00045	CcSEcCtD
Rabeprazole—Asthenia—Cisplatin—urinary bladder cancer	0.000135	0.000449	CcSEcCtD
Rabeprazole—Pharyngitis—Epirubicin—urinary bladder cancer	0.000135	0.000448	CcSEcCtD
Rabeprazole—Sweating—Doxorubicin—urinary bladder cancer	0.000135	0.000447	CcSEcCtD
Rabeprazole—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000135	0.000446	CcSEcCtD
Rabeprazole—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000134	0.000445	CcSEcCtD
Rabeprazole—Haematuria—Doxorubicin—urinary bladder cancer	0.000134	0.000444	CcSEcCtD
Rabeprazole—Urethral disorder—Epirubicin—urinary bladder cancer	0.000134	0.000443	CcSEcCtD
Rabeprazole—Epistaxis—Doxorubicin—urinary bladder cancer	0.000132	0.000439	CcSEcCtD
Rabeprazole—Angiopathy—Methotrexate—urinary bladder cancer	0.000132	0.000438	CcSEcCtD
Rabeprazole—Sinusitis—Doxorubicin—urinary bladder cancer	0.000132	0.000437	CcSEcCtD
Rabeprazole—Dizziness—Fluorouracil—urinary bladder cancer	0.000131	0.000436	CcSEcCtD
Rabeprazole—Visual impairment—Epirubicin—urinary bladder cancer	0.000131	0.000435	CcSEcCtD
Rabeprazole—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000131	0.000435	CcSEcCtD
Rabeprazole—Chills—Methotrexate—urinary bladder cancer	0.000131	0.000433	CcSEcCtD
Rabeprazole—Diarrhoea—Cisplatin—urinary bladder cancer	0.000129	0.000428	CcSEcCtD
Rabeprazole—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000129	0.000427	CcSEcCtD
Rabeprazole—Alopecia—Methotrexate—urinary bladder cancer	0.000129	0.000427	CcSEcCtD
Rabeprazole—Vomiting—Gemcitabine—urinary bladder cancer	0.000129	0.000426	CcSEcCtD
Rabeprazole—Bradycardia—Doxorubicin—urinary bladder cancer	0.000128	0.000426	CcSEcCtD
Rabeprazole—Rash—Gemcitabine—urinary bladder cancer	0.000127	0.000423	CcSEcCtD
Rabeprazole—Dermatitis—Gemcitabine—urinary bladder cancer	0.000127	0.000422	CcSEcCtD
Rabeprazole—Eye disorder—Epirubicin—urinary bladder cancer	0.000127	0.000422	CcSEcCtD
Rabeprazole—Hypersensitivity—Etoposide—urinary bladder cancer	0.000127	0.000422	CcSEcCtD
Rabeprazole—Tinnitus—Epirubicin—urinary bladder cancer	0.000127	0.000421	CcSEcCtD
Rabeprazole—Erythema—Methotrexate—urinary bladder cancer	0.000127	0.00042	CcSEcCtD
Rabeprazole—Malnutrition—Methotrexate—urinary bladder cancer	0.000127	0.00042	CcSEcCtD
Rabeprazole—Headache—Gemcitabine—urinary bladder cancer	0.000127	0.00042	CcSEcCtD
Rabeprazole—Vomiting—Fluorouracil—urinary bladder cancer	0.000126	0.000419	CcSEcCtD
Rabeprazole—Rhinitis—Doxorubicin—urinary bladder cancer	0.000126	0.000419	CcSEcCtD
Rabeprazole—Hepatitis—Doxorubicin—urinary bladder cancer	0.000126	0.000418	CcSEcCtD
Rabeprazole—Rash—Fluorouracil—urinary bladder cancer	0.000125	0.000416	CcSEcCtD
Rabeprazole—Dermatitis—Fluorouracil—urinary bladder cancer	0.000125	0.000415	CcSEcCtD
Rabeprazole—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000125	0.000415	CcSEcCtD
Rabeprazole—Headache—Fluorouracil—urinary bladder cancer	0.000125	0.000413	CcSEcCtD
Rabeprazole—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000124	0.000413	CcSEcCtD
Rabeprazole—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000124	0.000412	CcSEcCtD
Rabeprazole—Dysgeusia—Methotrexate—urinary bladder cancer	0.000124	0.000412	CcSEcCtD
Rabeprazole—Asthenia—Etoposide—urinary bladder cancer	0.000124	0.000411	CcSEcCtD
Rabeprazole—Angiopathy—Epirubicin—urinary bladder cancer	0.000124	0.00041	CcSEcCtD
Rabeprazole—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000124	0.00041	CcSEcCtD
Rabeprazole—Back pain—Methotrexate—urinary bladder cancer	0.000123	0.000407	CcSEcCtD
Rabeprazole—Chills—Epirubicin—urinary bladder cancer	0.000122	0.000405	CcSEcCtD
Rabeprazole—Pruritus—Etoposide—urinary bladder cancer	0.000122	0.000405	CcSEcCtD
Rabeprazole—Arrhythmia—Epirubicin—urinary bladder cancer	0.000122	0.000404	CcSEcCtD
Rabeprazole—Visual impairment—Doxorubicin—urinary bladder cancer	0.000121	0.000403	CcSEcCtD
Rabeprazole—Alopecia—Epirubicin—urinary bladder cancer	0.00012	0.000399	CcSEcCtD
Rabeprazole—Nausea—Gemcitabine—urinary bladder cancer	0.00012	0.000398	CcSEcCtD
Rabeprazole—Vomiting—Cisplatin—urinary bladder cancer	0.00012	0.000397	CcSEcCtD
Rabeprazole—Vision blurred—Methotrexate—urinary bladder cancer	0.000119	0.000396	CcSEcCtD
Rabeprazole—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000119	0.000395	CcSEcCtD
Rabeprazole—Rash—Cisplatin—urinary bladder cancer	0.000119	0.000394	CcSEcCtD
Rabeprazole—Dermatitis—Cisplatin—urinary bladder cancer	0.000119	0.000394	CcSEcCtD
Rabeprazole—Erythema—Epirubicin—urinary bladder cancer	0.000119	0.000393	CcSEcCtD
Rabeprazole—Malnutrition—Epirubicin—urinary bladder cancer	0.000119	0.000393	CcSEcCtD
Rabeprazole—Diarrhoea—Etoposide—urinary bladder cancer	0.000118	0.000392	CcSEcCtD
Rabeprazole—Nausea—Fluorouracil—urinary bladder cancer	0.000118	0.000392	CcSEcCtD
Rabeprazole—Eye disorder—Doxorubicin—urinary bladder cancer	0.000118	0.000391	CcSEcCtD
Rabeprazole—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000118	0.00039	CcSEcCtD
Rabeprazole—Tinnitus—Doxorubicin—urinary bladder cancer	0.000118	0.00039	CcSEcCtD
Rabeprazole—Anaemia—Methotrexate—urinary bladder cancer	0.000117	0.000388	CcSEcCtD
Rabeprazole—Flatulence—Epirubicin—urinary bladder cancer	0.000117	0.000388	CcSEcCtD
Rabeprazole—Tension—Epirubicin—urinary bladder cancer	0.000116	0.000386	CcSEcCtD
Rabeprazole—Dysgeusia—Epirubicin—urinary bladder cancer	0.000116	0.000385	CcSEcCtD
Rabeprazole—Nervousness—Epirubicin—urinary bladder cancer	0.000115	0.000382	CcSEcCtD
Rabeprazole—Back pain—Epirubicin—urinary bladder cancer	0.000115	0.00038	CcSEcCtD
Rabeprazole—Angiopathy—Doxorubicin—urinary bladder cancer	0.000114	0.000379	CcSEcCtD
Rabeprazole—Malaise—Methotrexate—urinary bladder cancer	0.000114	0.000379	CcSEcCtD
Rabeprazole—Dizziness—Etoposide—urinary bladder cancer	0.000114	0.000379	CcSEcCtD
Rabeprazole—Muscle spasms—Epirubicin—urinary bladder cancer	0.000114	0.000378	CcSEcCtD
Rabeprazole—Vertigo—Methotrexate—urinary bladder cancer	0.000114	0.000378	CcSEcCtD
Rabeprazole—Leukopenia—Methotrexate—urinary bladder cancer	0.000113	0.000376	CcSEcCtD
Rabeprazole—Chills—Doxorubicin—urinary bladder cancer	0.000113	0.000375	CcSEcCtD
Rabeprazole—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000113	0.000374	CcSEcCtD
Rabeprazole—Nausea—Cisplatin—urinary bladder cancer	0.000112	0.000371	CcSEcCtD
Rabeprazole—Vision blurred—Epirubicin—urinary bladder cancer	0.000112	0.000371	CcSEcCtD
Rabeprazole—Alopecia—Doxorubicin—urinary bladder cancer	0.000111	0.000369	CcSEcCtD
Rabeprazole—Cough—Methotrexate—urinary bladder cancer	0.000111	0.000367	CcSEcCtD
Rabeprazole—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.00011	0.000365	CcSEcCtD
Rabeprazole—Convulsion—Methotrexate—urinary bladder cancer	0.00011	0.000364	CcSEcCtD
Rabeprazole—Vomiting—Etoposide—urinary bladder cancer	0.00011	0.000364	CcSEcCtD
Rabeprazole—Erythema—Doxorubicin—urinary bladder cancer	0.00011	0.000364	CcSEcCtD
Rabeprazole—Malnutrition—Doxorubicin—urinary bladder cancer	0.00011	0.000364	CcSEcCtD
Rabeprazole—Anaemia—Epirubicin—urinary bladder cancer	0.00011	0.000364	CcSEcCtD
Rabeprazole—Agitation—Epirubicin—urinary bladder cancer	0.000109	0.000361	CcSEcCtD
Rabeprazole—Rash—Etoposide—urinary bladder cancer	0.000109	0.000361	CcSEcCtD
Rabeprazole—Dermatitis—Etoposide—urinary bladder cancer	0.000109	0.000361	CcSEcCtD
Rabeprazole—Headache—Etoposide—urinary bladder cancer	0.000108	0.000359	CcSEcCtD
Rabeprazole—Flatulence—Doxorubicin—urinary bladder cancer	0.000108	0.000359	CcSEcCtD
Rabeprazole—Arthralgia—Methotrexate—urinary bladder cancer	0.000108	0.000358	CcSEcCtD
Rabeprazole—Chest pain—Methotrexate—urinary bladder cancer	0.000108	0.000358	CcSEcCtD
Rabeprazole—Myalgia—Methotrexate—urinary bladder cancer	0.000108	0.000358	CcSEcCtD
Rabeprazole—Tension—Doxorubicin—urinary bladder cancer	0.000108	0.000357	CcSEcCtD
Rabeprazole—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000107	0.000356	CcSEcCtD
Rabeprazole—Malaise—Epirubicin—urinary bladder cancer	0.000107	0.000355	CcSEcCtD
Rabeprazole—Discomfort—Methotrexate—urinary bladder cancer	0.000107	0.000354	CcSEcCtD
Rabeprazole—Nervousness—Doxorubicin—urinary bladder cancer	0.000107	0.000353	CcSEcCtD
Rabeprazole—Vertigo—Epirubicin—urinary bladder cancer	0.000107	0.000353	CcSEcCtD
Rabeprazole—Syncope—Epirubicin—urinary bladder cancer	0.000106	0.000353	CcSEcCtD
Rabeprazole—Leukopenia—Epirubicin—urinary bladder cancer	0.000106	0.000352	CcSEcCtD
Rabeprazole—Back pain—Doxorubicin—urinary bladder cancer	0.000106	0.000352	CcSEcCtD
Rabeprazole—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000105	0.00035	CcSEcCtD
Rabeprazole—Palpitations—Epirubicin—urinary bladder cancer	0.000105	0.000348	CcSEcCtD
Rabeprazole—Confusional state—Methotrexate—urinary bladder cancer	0.000104	0.000346	CcSEcCtD
Rabeprazole—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000104	0.000346	CcSEcCtD
Rabeprazole—Cough—Epirubicin—urinary bladder cancer	0.000103	0.000343	CcSEcCtD
Rabeprazole—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000103	0.000343	CcSEcCtD
Rabeprazole—Vision blurred—Doxorubicin—urinary bladder cancer	0.000103	0.000343	CcSEcCtD
Rabeprazole—Convulsion—Epirubicin—urinary bladder cancer	0.000103	0.000341	CcSEcCtD
Rabeprazole—Nausea—Etoposide—urinary bladder cancer	0.000103	0.00034	CcSEcCtD
Rabeprazole—Hypertension—Epirubicin—urinary bladder cancer	0.000102	0.00034	CcSEcCtD
Rabeprazole—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000102	0.000338	CcSEcCtD
Rabeprazole—Anaemia—Doxorubicin—urinary bladder cancer	0.000101	0.000336	CcSEcCtD
Rabeprazole—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000101	0.000336	CcSEcCtD
Rabeprazole—Myalgia—Epirubicin—urinary bladder cancer	0.000101	0.000335	CcSEcCtD
Rabeprazole—Arthralgia—Epirubicin—urinary bladder cancer	0.000101	0.000335	CcSEcCtD
Rabeprazole—Chest pain—Epirubicin—urinary bladder cancer	0.000101	0.000335	CcSEcCtD
Rabeprazole—Agitation—Doxorubicin—urinary bladder cancer	0.000101	0.000334	CcSEcCtD
Rabeprazole—Anxiety—Epirubicin—urinary bladder cancer	0.000101	0.000334	CcSEcCtD
Rabeprazole—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.0001	0.000332	CcSEcCtD
Rabeprazole—Discomfort—Epirubicin—urinary bladder cancer	9.97e-05	0.000331	CcSEcCtD
Rabeprazole—Malaise—Doxorubicin—urinary bladder cancer	9.89e-05	0.000328	CcSEcCtD
Rabeprazole—Dry mouth—Epirubicin—urinary bladder cancer	9.87e-05	0.000328	CcSEcCtD
Rabeprazole—Vertigo—Doxorubicin—urinary bladder cancer	9.86e-05	0.000327	CcSEcCtD
Rabeprazole—Anorexia—Methotrexate—urinary bladder cancer	9.86e-05	0.000327	CcSEcCtD
Rabeprazole—Syncope—Doxorubicin—urinary bladder cancer	9.84e-05	0.000326	CcSEcCtD
Rabeprazole—Leukopenia—Doxorubicin—urinary bladder cancer	9.82e-05	0.000326	CcSEcCtD
Rabeprazole—Confusional state—Epirubicin—urinary bladder cancer	9.76e-05	0.000324	CcSEcCtD
Rabeprazole—Palpitations—Doxorubicin—urinary bladder cancer	9.7e-05	0.000322	CcSEcCtD
Rabeprazole—Anaphylactic shock—Epirubicin—urinary bladder cancer	9.68e-05	0.000321	CcSEcCtD
Rabeprazole—Oedema—Epirubicin—urinary bladder cancer	9.68e-05	0.000321	CcSEcCtD
Rabeprazole—Hypotension—Methotrexate—urinary bladder cancer	9.66e-05	0.000321	CcSEcCtD
Rabeprazole—Loss of consciousness—Doxorubicin—urinary bladder cancer	9.64e-05	0.00032	CcSEcCtD
Rabeprazole—Cough—Doxorubicin—urinary bladder cancer	9.57e-05	0.000318	CcSEcCtD
Rabeprazole—Shock—Epirubicin—urinary bladder cancer	9.52e-05	0.000316	CcSEcCtD
Rabeprazole—Convulsion—Doxorubicin—urinary bladder cancer	9.51e-05	0.000315	CcSEcCtD
Rabeprazole—Thrombocytopenia—Epirubicin—urinary bladder cancer	9.48e-05	0.000314	CcSEcCtD
Rabeprazole—Hypertension—Doxorubicin—urinary bladder cancer	9.47e-05	0.000314	CcSEcCtD
Rabeprazole—Tachycardia—Epirubicin—urinary bladder cancer	9.45e-05	0.000313	CcSEcCtD
Rabeprazole—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	9.42e-05	0.000313	CcSEcCtD
Rabeprazole—Hyperhidrosis—Epirubicin—urinary bladder cancer	9.36e-05	0.00031	CcSEcCtD
Rabeprazole—Insomnia—Methotrexate—urinary bladder cancer	9.35e-05	0.00031	CcSEcCtD
Rabeprazole—Chest pain—Doxorubicin—urinary bladder cancer	9.34e-05	0.00031	CcSEcCtD
Rabeprazole—Myalgia—Doxorubicin—urinary bladder cancer	9.34e-05	0.00031	CcSEcCtD
Rabeprazole—Arthralgia—Doxorubicin—urinary bladder cancer	9.34e-05	0.00031	CcSEcCtD
Rabeprazole—Anxiety—Doxorubicin—urinary bladder cancer	9.31e-05	0.000309	CcSEcCtD
Rabeprazole—Paraesthesia—Methotrexate—urinary bladder cancer	9.29e-05	0.000308	CcSEcCtD
Rabeprazole—Discomfort—Doxorubicin—urinary bladder cancer	9.23e-05	0.000306	CcSEcCtD
Rabeprazole—Anorexia—Epirubicin—urinary bladder cancer	9.22e-05	0.000306	CcSEcCtD
Rabeprazole—Dyspnoea—Methotrexate—urinary bladder cancer	9.22e-05	0.000306	CcSEcCtD
Rabeprazole—Somnolence—Methotrexate—urinary bladder cancer	9.19e-05	0.000305	CcSEcCtD
Rabeprazole—Dry mouth—Doxorubicin—urinary bladder cancer	9.14e-05	0.000303	CcSEcCtD
Rabeprazole—Dyspepsia—Methotrexate—urinary bladder cancer	9.1e-05	0.000302	CcSEcCtD
Rabeprazole—Hypotension—Epirubicin—urinary bladder cancer	9.04e-05	0.0003	CcSEcCtD
Rabeprazole—Confusional state—Doxorubicin—urinary bladder cancer	9.03e-05	0.0003	CcSEcCtD
Rabeprazole—Decreased appetite—Methotrexate—urinary bladder cancer	8.99e-05	0.000298	CcSEcCtD
Rabeprazole—Anaphylactic shock—Doxorubicin—urinary bladder cancer	8.95e-05	0.000297	CcSEcCtD
Rabeprazole—Oedema—Doxorubicin—urinary bladder cancer	8.95e-05	0.000297	CcSEcCtD
Rabeprazole—Pain—Methotrexate—urinary bladder cancer	8.84e-05	0.000293	CcSEcCtD
Rabeprazole—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	8.82e-05	0.000292	CcSEcCtD
Rabeprazole—Shock—Doxorubicin—urinary bladder cancer	8.81e-05	0.000292	CcSEcCtD
Rabeprazole—Thrombocytopenia—Doxorubicin—urinary bladder cancer	8.77e-05	0.000291	CcSEcCtD
Rabeprazole—Insomnia—Epirubicin—urinary bladder cancer	8.75e-05	0.00029	CcSEcCtD
Rabeprazole—Tachycardia—Doxorubicin—urinary bladder cancer	8.74e-05	0.00029	CcSEcCtD
Rabeprazole—Paraesthesia—Epirubicin—urinary bladder cancer	8.69e-05	0.000288	CcSEcCtD
Rabeprazole—Hyperhidrosis—Doxorubicin—urinary bladder cancer	8.66e-05	0.000287	CcSEcCtD
Rabeprazole—Dyspnoea—Epirubicin—urinary bladder cancer	8.63e-05	0.000286	CcSEcCtD
Rabeprazole—Somnolence—Epirubicin—urinary bladder cancer	8.6e-05	0.000285	CcSEcCtD
Rabeprazole—Anorexia—Doxorubicin—urinary bladder cancer	8.54e-05	0.000283	CcSEcCtD
Rabeprazole—Feeling abnormal—Methotrexate—urinary bladder cancer	8.52e-05	0.000283	CcSEcCtD
Rabeprazole—Dyspepsia—Epirubicin—urinary bladder cancer	8.52e-05	0.000283	CcSEcCtD
Rabeprazole—Gastrointestinal pain—Methotrexate—urinary bladder cancer	8.46e-05	0.000281	CcSEcCtD
Rabeprazole—Decreased appetite—Epirubicin—urinary bladder cancer	8.41e-05	0.000279	CcSEcCtD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	8.39e-05	0.000812	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	8.39e-05	0.000812	CbGpPWpGaD
Rabeprazole—Hypotension—Doxorubicin—urinary bladder cancer	8.37e-05	0.000278	CcSEcCtD
Rabeprazole—ABCG2—Metabolism—UGT2B7—urinary bladder cancer	8.35e-05	0.000807	CbGpPWpGaD
Rabeprazole—Pain—Epirubicin—urinary bladder cancer	8.28e-05	0.000275	CcSEcCtD
Rabeprazole—Constipation—Epirubicin—urinary bladder cancer	8.28e-05	0.000275	CcSEcCtD
Rabeprazole—Urticaria—Methotrexate—urinary bladder cancer	8.22e-05	0.000273	CcSEcCtD
Rabeprazole—Body temperature increased—Methotrexate—urinary bladder cancer	8.18e-05	0.000271	CcSEcCtD
Rabeprazole—Abdominal pain—Methotrexate—urinary bladder cancer	8.18e-05	0.000271	CcSEcCtD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	8.16e-05	0.000789	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	8.16e-05	0.000789	CbGpPWpGaD
Rabeprazole—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	8.16e-05	0.000271	CcSEcCtD
Rabeprazole—Insomnia—Doxorubicin—urinary bladder cancer	8.1e-05	0.000269	CcSEcCtD
Rabeprazole—Paraesthesia—Doxorubicin—urinary bladder cancer	8.04e-05	0.000267	CcSEcCtD
Rabeprazole—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	8.01e-05	0.000774	CbGpPWpGaD
Rabeprazole—CYP2C19—Biological oxidations—GSTM1—urinary bladder cancer	8e-05	0.000774	CbGpPWpGaD
Rabeprazole—Dyspnoea—Doxorubicin—urinary bladder cancer	7.98e-05	0.000265	CcSEcCtD
Rabeprazole—Feeling abnormal—Epirubicin—urinary bladder cancer	7.98e-05	0.000265	CcSEcCtD
Rabeprazole—Somnolence—Doxorubicin—urinary bladder cancer	7.96e-05	0.000264	CcSEcCtD
Rabeprazole—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	7.94e-05	0.000768	CbGpPWpGaD
Rabeprazole—Gastrointestinal pain—Epirubicin—urinary bladder cancer	7.91e-05	0.000263	CcSEcCtD
Rabeprazole—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	7.9e-05	0.000764	CbGpPWpGaD
Rabeprazole—CYP2C19—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.89e-05	0.000763	CbGpPWpGaD
Rabeprazole—Dyspepsia—Doxorubicin—urinary bladder cancer	7.88e-05	0.000261	CcSEcCtD
Rabeprazole—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	7.83e-05	0.000757	CbGpPWpGaD
Rabeprazole—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	7.79e-05	0.000753	CbGpPWpGaD
Rabeprazole—Decreased appetite—Doxorubicin—urinary bladder cancer	7.78e-05	0.000258	CcSEcCtD
Rabeprazole—ABCG2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	7.76e-05	0.00075	CbGpPWpGaD
Rabeprazole—Urticaria—Epirubicin—urinary bladder cancer	7.69e-05	0.000255	CcSEcCtD
Rabeprazole—Pain—Doxorubicin—urinary bladder cancer	7.66e-05	0.000254	CcSEcCtD
Rabeprazole—Constipation—Doxorubicin—urinary bladder cancer	7.66e-05	0.000254	CcSEcCtD
Rabeprazole—Body temperature increased—Epirubicin—urinary bladder cancer	7.65e-05	0.000254	CcSEcCtD
Rabeprazole—Abdominal pain—Epirubicin—urinary bladder cancer	7.65e-05	0.000254	CcSEcCtD
Rabeprazole—Hypersensitivity—Methotrexate—urinary bladder cancer	7.62e-05	0.000253	CcSEcCtD
Rabeprazole—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	7.55e-05	0.00073	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—CYP4B1—urinary bladder cancer	7.51e-05	0.000727	CbGpPWpGaD
Rabeprazole—Asthenia—Methotrexate—urinary bladder cancer	7.42e-05	0.000246	CcSEcCtD
Rabeprazole—Feeling abnormal—Doxorubicin—urinary bladder cancer	7.38e-05	0.000245	CcSEcCtD
Rabeprazole—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	7.36e-05	0.000712	CbGpPWpGaD
Rabeprazole—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	7.32e-05	0.000243	CcSEcCtD
Rabeprazole—Pruritus—Methotrexate—urinary bladder cancer	7.32e-05	0.000243	CcSEcCtD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	7.31e-05	0.000707	CbGpPWpGaD
Rabeprazole—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	7.29e-05	0.000705	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	7.28e-05	0.000704	CbGpPWpGaD
Rabeprazole—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.26e-05	0.000702	CbGpPWpGaD
Rabeprazole—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.19e-05	0.000696	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	7.15e-05	0.000692	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	7.15e-05	0.000692	CbGpPWpGaD
Rabeprazole—Hypersensitivity—Epirubicin—urinary bladder cancer	7.13e-05	0.000237	CcSEcCtD
Rabeprazole—Urticaria—Doxorubicin—urinary bladder cancer	7.11e-05	0.000236	CcSEcCtD
Rabeprazole—ABCG2—Metabolism—SLC19A1—urinary bladder cancer	7.1e-05	0.000686	CbGpPWpGaD
Rabeprazole—Body temperature increased—Doxorubicin—urinary bladder cancer	7.08e-05	0.000235	CcSEcCtD
Rabeprazole—Abdominal pain—Doxorubicin—urinary bladder cancer	7.08e-05	0.000235	CcSEcCtD
Rabeprazole—Diarrhoea—Methotrexate—urinary bladder cancer	7.08e-05	0.000235	CcSEcCtD
Rabeprazole—Asthenia—Epirubicin—urinary bladder cancer	6.94e-05	0.00023	CcSEcCtD
Rabeprazole—ABCG2—Metabolism—PRSS3—urinary bladder cancer	6.92e-05	0.000669	CbGpPWpGaD
Rabeprazole—Pruritus—Epirubicin—urinary bladder cancer	6.85e-05	0.000227	CcSEcCtD
Rabeprazole—Dizziness—Methotrexate—urinary bladder cancer	6.84e-05	0.000227	CcSEcCtD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	6.81e-05	0.000659	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	6.81e-05	0.000659	CbGpPWpGaD
Rabeprazole—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	6.78e-05	0.000656	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	6.76e-05	0.000654	CbGpPWpGaD
Rabeprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—urinary bladder cancer	6.75e-05	0.000653	CbGpPWpGaD
Rabeprazole—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	6.69e-05	0.000647	CbGpPWpGaD
Rabeprazole—Diarrhoea—Epirubicin—urinary bladder cancer	6.62e-05	0.00022	CcSEcCtD
Rabeprazole—Hypersensitivity—Doxorubicin—urinary bladder cancer	6.6e-05	0.000219	CcSEcCtD
Rabeprazole—Vomiting—Methotrexate—urinary bladder cancer	6.58e-05	0.000218	CcSEcCtD
Rabeprazole—CYP1A1—PPARA activates gene expression—EP300—urinary bladder cancer	6.55e-05	0.000634	CbGpPWpGaD
Rabeprazole—Rash—Methotrexate—urinary bladder cancer	6.52e-05	0.000216	CcSEcCtD
Rabeprazole—CYP1A1—Metabolism—GSTZ1—urinary bladder cancer	6.52e-05	0.00063	CbGpPWpGaD
Rabeprazole—Dermatitis—Methotrexate—urinary bladder cancer	6.51e-05	0.000216	CcSEcCtD
Rabeprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CREBBP—urinary bladder cancer	6.49e-05	0.000628	CbGpPWpGaD
Rabeprazole—Headache—Methotrexate—urinary bladder cancer	6.48e-05	0.000215	CcSEcCtD
Rabeprazole—Asthenia—Doxorubicin—urinary bladder cancer	6.42e-05	0.000213	CcSEcCtD
Rabeprazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—urinary bladder cancer	6.41e-05	0.00062	CbGpPWpGaD
Rabeprazole—Dizziness—Epirubicin—urinary bladder cancer	6.4e-05	0.000212	CcSEcCtD
Rabeprazole—Pruritus—Doxorubicin—urinary bladder cancer	6.34e-05	0.00021	CcSEcCtD
Rabeprazole—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	6.23e-05	0.000603	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—GSTO2—urinary bladder cancer	6.18e-05	0.000597	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—NAT1—urinary bladder cancer	6.18e-05	0.000597	CbGpPWpGaD
Rabeprazole—Vomiting—Epirubicin—urinary bladder cancer	6.15e-05	0.000204	CcSEcCtD
Rabeprazole—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	6.15e-05	0.000594	CbGpPWpGaD
Rabeprazole—Nausea—Methotrexate—urinary bladder cancer	6.14e-05	0.000204	CcSEcCtD
Rabeprazole—Diarrhoea—Doxorubicin—urinary bladder cancer	6.13e-05	0.000203	CcSEcCtD
Rabeprazole—Rash—Epirubicin—urinary bladder cancer	6.1e-05	0.000202	CcSEcCtD
Rabeprazole—Dermatitis—Epirubicin—urinary bladder cancer	6.1e-05	0.000202	CcSEcCtD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.08e-05	0.000588	CbGpPWpGaD
Rabeprazole—Headache—Epirubicin—urinary bladder cancer	6.06e-05	0.000201	CcSEcCtD
Rabeprazole—Dizziness—Doxorubicin—urinary bladder cancer	5.92e-05	0.000196	CcSEcCtD
Rabeprazole—Nausea—Epirubicin—urinary bladder cancer	5.75e-05	0.000191	CcSEcCtD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	5.74e-05	0.000556	CbGpPWpGaD
Rabeprazole—Vomiting—Doxorubicin—urinary bladder cancer	5.69e-05	0.000189	CcSEcCtD
Rabeprazole—CYP1A1—Metabolism—UGT2B7—urinary bladder cancer	5.65e-05	0.000546	CbGpPWpGaD
Rabeprazole—Rash—Doxorubicin—urinary bladder cancer	5.65e-05	0.000187	CcSEcCtD
Rabeprazole—Dermatitis—Doxorubicin—urinary bladder cancer	5.64e-05	0.000187	CcSEcCtD
Rabeprazole—Headache—Doxorubicin—urinary bladder cancer	5.61e-05	0.000186	CcSEcCtD
Rabeprazole—ABCG2—Metabolism—TYMP—urinary bladder cancer	5.53e-05	0.000535	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	5.33e-05	0.000516	CbGpPWpGaD
Rabeprazole—Nausea—Doxorubicin—urinary bladder cancer	5.32e-05	0.000176	CcSEcCtD
Rabeprazole—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	5.23e-05	0.000506	CbGpPWpGaD
Rabeprazole—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	5.16e-05	0.000499	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—CYP4B1—urinary bladder cancer	5.09e-05	0.000492	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	5.05e-05	0.000489	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—NAT1—urinary bladder cancer	5.05e-05	0.000489	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—NAT2—urinary bladder cancer	5e-05	0.000484	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4.97e-05	0.000481	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	4.9e-05	0.000474	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	4.86e-05	0.00047	CbGpPWpGaD
Rabeprazole—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	4.81e-05	0.000465	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—SLC19A1—urinary bladder cancer	4.8e-05	0.000465	CbGpPWpGaD
Rabeprazole—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	4.74e-05	0.000459	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—PRSS3—urinary bladder cancer	4.68e-05	0.000453	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	4.65e-05	0.00045	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—NAT1—urinary bladder cancer	4.65e-05	0.00045	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	4.62e-05	0.000447	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	4.61e-05	0.000446	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—NAT1—urinary bladder cancer	4.61e-05	0.000446	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4.53e-05	0.000438	CbGpPWpGaD
Rabeprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	4.42e-05	0.000427	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—RRM2—urinary bladder cancer	4.32e-05	0.000417	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	4.25e-05	0.000411	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	4.22e-05	0.000408	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	4.16e-05	0.000403	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	4.15e-05	0.000402	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—ENO2—urinary bladder cancer	4e-05	0.000387	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—HPGDS—urinary bladder cancer	4e-05	0.000387	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	3.94e-05	0.000381	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—NAT1—urinary bladder cancer	3.94e-05	0.000381	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	3.93e-05	0.00038	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—GSTT1—urinary bladder cancer	3.88e-05	0.000375	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.87e-05	0.000375	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	3.83e-05	0.000371	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	3.83e-05	0.00037	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	3.8e-05	0.000367	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.75e-05	0.000363	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—TYMP—urinary bladder cancer	3.74e-05	0.000362	CbGpPWpGaD
Rabeprazole—ABCG2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.63e-05	0.000351	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	3.62e-05	0.00035	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	3.6e-05	0.000348	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.59e-05	0.000348	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	3.58e-05	0.000347	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	3.52e-05	0.000341	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	3.49e-05	0.000338	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—NAT2—urinary bladder cancer	3.38e-05	0.000327	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	3.24e-05	0.000314	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—NQO1—urinary bladder cancer	3.22e-05	0.000312	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	3.21e-05	0.00031	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.07e-05	0.000297	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	3.06e-05	0.000296	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—TYMP—urinary bladder cancer	3.06e-05	0.000296	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	3.04e-05	0.000294	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—NAT1—urinary bladder cancer	3.04e-05	0.000294	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	2.98e-05	0.000289	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.94e-05	0.000284	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—RRM2—urinary bladder cancer	2.92e-05	0.000283	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—TYMP—urinary bladder cancer	2.82e-05	0.000272	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.8e-05	0.000271	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—TYMP—urinary bladder cancer	2.79e-05	0.00027	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.78e-05	0.000269	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—NAT2—urinary bladder cancer	2.77e-05	0.000268	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—ENO2—urinary bladder cancer	2.71e-05	0.000262	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—HPGDS—urinary bladder cancer	2.71e-05	0.000262	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.69e-05	0.00026	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—GSTP1—urinary bladder cancer	2.69e-05	0.00026	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.68e-05	0.000259	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—GSTT1—urinary bladder cancer	2.62e-05	0.000254	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.58e-05	0.00025	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—NAT2—urinary bladder cancer	2.55e-05	0.000246	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—NAT2—urinary bladder cancer	2.53e-05	0.000244	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	2.5e-05	0.000242	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—TYMS—urinary bladder cancer	2.5e-05	0.000242	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—NCOR1—urinary bladder cancer	2.47e-05	0.000239	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—GSTM1—urinary bladder cancer	2.47e-05	0.000239	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.39e-05	0.000231	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—RRM2—urinary bladder cancer	2.39e-05	0.000231	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—TYMP—urinary bladder cancer	2.39e-05	0.000231	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—GPX1—urinary bladder cancer	2.36e-05	0.000229	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.36e-05	0.000229	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—ERCC2—urinary bladder cancer	2.32e-05	0.000225	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.3e-05	0.000223	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.29e-05	0.000222	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—ENO2—urinary bladder cancer	2.21e-05	0.000214	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	2.21e-05	0.000214	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.2e-05	0.000213	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—RRM2—urinary bladder cancer	2.2e-05	0.000213	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—MTHFR—urinary bladder cancer	2.18e-05	0.000211	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—NQO1—urinary bladder cancer	2.18e-05	0.000211	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—RRM2—urinary bladder cancer	2.18e-05	0.000211	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—NAT2—urinary bladder cancer	2.16e-05	0.000209	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	2.15e-05	0.000208	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.12e-05	0.000205	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.11e-05	0.000205	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	2.04e-05	0.000197	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—ENO2—urinary bladder cancer	2.04e-05	0.000197	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—ENO2—urinary bladder cancer	2.02e-05	0.000195	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	2.02e-05	0.000195	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.01e-05	0.000194	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	1.98e-05	0.000191	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.96e-05	0.000189	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.93e-05	0.000186	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—RRM2—urinary bladder cancer	1.86e-05	0.00018	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.85e-05	0.000178	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.84e-05	0.000178	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—GSTP1—urinary bladder cancer	1.82e-05	0.000176	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—NQO1—urinary bladder cancer	1.78e-05	0.000173	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—PPARG—urinary bladder cancer	1.77e-05	0.000171	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.76e-05	0.00017	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.73e-05	0.000167	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	1.73e-05	0.000167	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—ENO2—urinary bladder cancer	1.73e-05	0.000167	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.72e-05	0.000166	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—CREBBP—urinary bladder cancer	1.7e-05	0.000164	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—TYMS—urinary bladder cancer	1.69e-05	0.000164	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	1.67e-05	0.000162	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—GSTM1—urinary bladder cancer	1.67e-05	0.000162	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—NCOR1—urinary bladder cancer	1.67e-05	0.000162	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.67e-05	0.000161	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.65e-05	0.000159	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.64e-05	0.000159	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.63e-05	0.000157	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—GPX1—urinary bladder cancer	1.6e-05	0.000155	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.58e-05	0.000153	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—ERCC2—urinary bladder cancer	1.57e-05	0.000152	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.51e-05	0.000146	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	1.49e-05	0.000144	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—MTHFR—urinary bladder cancer	1.48e-05	0.000143	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.44e-05	0.000139	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.44e-05	0.000139	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—PTGS2—urinary bladder cancer	1.39e-05	0.000135	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.39e-05	0.000134	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—TYMS—urinary bladder cancer	1.38e-05	0.000134	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.38e-05	0.000133	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.37e-05	0.000132	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	1.37e-05	0.000132	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	1.37e-05	0.000132	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.36e-05	0.000131	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.35e-05	0.00013	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.33e-05	0.000129	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.33e-05	0.000129	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.31e-05	0.000127	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—GPX1—urinary bladder cancer	1.31e-05	0.000127	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.29e-05	0.000125	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	1.29e-05	0.000124	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.27e-05	0.000123	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.26e-05	0.000122	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.26e-05	0.000122	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.26e-05	0.000122	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.25e-05	0.000121	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.25e-05	0.000121	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—PTEN—urinary bladder cancer	1.21e-05	0.000117	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.21e-05	0.000117	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.2e-05	0.000117	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—PPARG—urinary bladder cancer	1.2e-05	0.000116	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.19e-05	0.000116	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.18e-05	0.000114	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.18e-05	0.000114	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.17e-05	0.000113	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.16e-05	0.000112	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—EP300—urinary bladder cancer	1.16e-05	0.000112	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	1.15e-05	0.000111	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.12e-05	0.000109	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.11e-05	0.000108	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.1e-05	0.000107	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.08e-05	0.000104	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.07e-05	0.000104	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.07e-05	0.000103	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.07e-05	0.000103	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.02e-05	9.87e-05	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1e-05	9.69e-05	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—PPARG—urinary bladder cancer	9.8e-06	9.48e-05	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	9.42e-06	9.11e-05	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	9.42e-06	9.11e-05	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	9.42e-06	9.11e-05	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—PPARG—urinary bladder cancer	9.02e-06	8.72e-05	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	8.95e-06	8.66e-05	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—PPARG—urinary bladder cancer	8.94e-06	8.65e-05	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	8.66e-06	8.38e-05	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	8.59e-06	8.3e-05	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—TYMS—urinary bladder cancer	8.32e-06	8.05e-05	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	8.23e-06	7.96e-05	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	8.23e-06	7.96e-05	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—PTEN—urinary bladder cancer	8.22e-06	7.95e-05	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—GPX1—urinary bladder cancer	7.88e-06	7.62e-05	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—EP300—urinary bladder cancer	7.84e-06	7.58e-05	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	7.73e-06	7.48e-05	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	7.71e-06	7.46e-05	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—PPARG—urinary bladder cancer	7.64e-06	7.39e-05	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	7.34e-06	7.1e-05	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	7.27e-06	7.03e-05	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	7.09e-06	6.86e-05	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	7.03e-06	6.8e-05	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—PTEN—urinary bladder cancer	6.73e-06	6.5e-05	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—EP300—urinary bladder cancer	6.41e-06	6.2e-05	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—PTEN—urinary bladder cancer	6.19e-06	5.98e-05	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—PTEN—urinary bladder cancer	6.13e-06	5.93e-05	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	6.01e-06	5.81e-05	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—EP300—urinary bladder cancer	5.9e-06	5.71e-05	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—PPARG—urinary bladder cancer	5.89e-06	5.7e-05	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—EP300—urinary bladder cancer	5.85e-06	5.66e-05	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	5.66e-06	5.48e-05	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—PTEN—urinary bladder cancer	5.24e-06	5.07e-05	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—EP300—urinary bladder cancer	5e-06	4.83e-05	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	4.64e-06	4.49e-05	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—PTEN—urinary bladder cancer	4.04e-06	3.91e-05	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.86e-06	3.73e-05	CbGpPWpGaD
